semaglutide
7 Retatrutide Outscores Semaglutide in MC4R
In the latest multicenter RCT, retatrutide achieved a 23.4% body-fat reduction, outpacing semaglutide’s 15.2% and tirzepatide’s 19.6% in patients with MC4R deficiency. The study enrolled 1,200 adults across 30 sites and followed them for 48 weeks, offering the most comprehensive head-to-head comparison to date.